Bellicum enrolls first patient in phase 1/2 clinical trial for bpx-603

Houston, dec. 10, 2020 (globe newswire) -- bellicum pharmaceuticals, inc. (nasdaq:blcm), a leader in developing novel, controllable cellular immunotherapies for cancers, today announced enrollment and apheresis of the first patient in the phase 1/2 clinical trial for bpx-603 in patients with tumors that express human epidermal growth factor 2 (her2). bpx-603 is bellicum's first dual switch gocar-t® product candidate that incorporates the company's imc activation and caspacide® safety switch technologies.
BLCM Ratings Summary
BLCM Quant Ranking